Results 51 to 60 of about 576 (142)

The Immunometabolomic Interface Receptor Hydroxycarboxylic Acid Receptor 2 Mediates the Therapeutic Effects of Dimethyl Fumarate in Autoantibody-Induced Skin Inflammation

Frontiers in Immunology, 2018
The drug dimethyl fumarate (DMF) is in clinical use for the treatment of psoriasis and multiple sclerosis. In addition, it has recently been demonstrated to ameliorate skin pathology in mouse models of pemphigoid diseases, a group of autoimmune ...
Melanie Wannick, Julian C. Assmann, Jakob F. Vielhauer, Stefan Offermanns, Detlef Zillikens, Christian D. Sadik, Markus Schwaninger   +6 more
doaj   +1 more source

Immunofluorescence testing in the diagnosis of autoimmune blistering diseases: overview of 10-year experience [PDF]

Anais Brasileiros de Dermatologia, 2014
BACKGROUND: Immunofluorescence testing is an important tool for diagnosing blistering diseases. OBJECTIVE: To characterize the immunofluorescence findings in patients diagnosed with autoimmune blistering skin diseases.
Samia Trigo Arbache, Tarsila Gasparotto Nogueira, Lívia Delgado, Denise Miyamoto, Valéria Aoki   +4 more
doaj   +1 more source

Monocyte populations are involved in the pathogenesis of experimental epidermolysis bullosa acquisita

Frontiers in Immunology, 2023
Monocytes play a significant role in the pathogenesis of most inflammatory diseases, including autoimmune diseases. Herein, different subpopulations of monocytes often play differential, partially antagonistic roles, in the regulation of tissue ...
Reza Akbarzadeh, Reza Akbarzadeh, Christianna Czyz, Sarah-Yasmin Thomsen, Paul Schilf, Sripriya Murthy, Christian D. Sadik, Peter König   +7 more
doaj   +1 more source

Klinisches und immunpathologisches Spektrum des Immunglobulin‐M‐Pemphigoids: eine multizentrische Fallserie

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 23, Issue 12, Page 1555-1565, December 2025.
Zusammenfassung Hintergrund und Zielsetzung Die Pemphigoid‐Erkrankungen werden primär durch IgG‐ oder IgA‐Autoantikörper gegen die kutane Basalmembranzone (BMZ) vermittelt. Obwohl rezente Arbeiten auf die Existenz einer ausschließlich IgM‐vermittelten Pemphigoid‐Erkrankung hindeuten, fehlt bislang eine umfassendere Untersuchung.
Kaan Yilmaz, Stephanie Goletz, Christoph M. Hammers, Katharina Boch, Claudia Zeidler, Henning Wiegmann, Estelle Bergmann, Tina Rastegar Lari, Onur Dikmen, Nina Häring, Robert Strohal, Andreas Kleinheinz, Eva N. Hadaschik, Nina van Beek, Sonja Ständer, Enno Schmidt   +15 more
wiley   +1 more source

Therapeutic Effect of a Novel Phosphatidylinositol-3-Kinase δ Inhibitor in Experimental Epidermolysis Bullosa Acquisita

Frontiers in Immunology, 2018
Epidermolysis bullosa acquisita (EBA) is a rare, but prototypical, organ-specific autoimmune disease, characterized and caused by autoantibodies against type VII collagen (COL7).
Hiroshi Koga, Anika Kasprick, Rosa López, Mariona Aulí, Mercè Pont, Núria Godessart, Detlef Zillikens, Katja Bieber, Ralf J. Ludwig, Ralf J. Ludwig, Cristina Balagué   +10 more
doaj   +1 more source

Development of Japanese versions of the Autoimmune Bullous Disease Quality of Life and Treatment of Autoimmune Bullous Disease Quality of Life questionnaires

The Journal of Dermatology, Volume 52, Issue 5, Page 812-830, May 2025.
Abstract Patients with autoimmune bullous disease have their quality of life (QOL) affected by both the disease and its treatment burden. While QOL assessment is clinically important, it is often hindered by limited time in clinical practice, highlighting the need for accurate and efficient QOL evaluation tools. However, no validated QOL questionnaires
Chika Tanemura, Maya Nunotani, Kyoko Kawabata, Yuki Morooka, Jun Yamagami, Risa Kakuta, Yasuko Saito, Yuichi Kurihara, Hayato Takahashi, Norito Ishii, Hiroshi Koga, Takekuni Nakama, Daisuke Hayashi, Sho Hiroyasu, Chiharu Tateishi, Daisuke Tsuruta, Dedee F. Murrell, Takashi Hashimoto   +17 more
wiley   +1 more source

A Case of Palmoplantar Vesiculobullous Lesions

JEADV Clinical Practice, Volume 5, Issue 1, Page 315-318, March 2026.
Ali Abid, Kelvin Truong, Jing Jing Li, Artiene Tatian   +3 more
wiley   +1 more source

Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients

Orphanet Journal of Rare Diseases, 2018
Background Epidermolysis bullosa acquisita (EBA) is an orphan autoimmune disease. Several clinical phenotypes have been described, but subepidermal blistering is characteristic of all variants.
Hiroaki Iwata, Artem Vorobyev, Hiroshi Koga, Andreas Recke, Detlef Zillikens, Catherine Prost-Squarcioni, Norito Ishii, Takashi Hashimoto, Ralf J. Ludwig   +8 more
doaj   +1 more source

Fcγ Receptor IIB Controls Skin Inflammation in an Active Model of Epidermolysis Bullosa Acquisita

Frontiers in Immunology, 2020
Epidermolysis bullosa acquisita (EBA) is an autoimmune skin blistering disease characterized by IgG autoantibodies (aAb) against type VII collagen (COL7).
Balint Kovacs, Balint Kovacs, Jenny Tillmann, Lisa-Christin Freund, Falk Nimmerjahn, Christian D. Sadik, Katja Bieber, Ralf J. Ludwig, Christian M. Karsten, Jörg Köhl, Jörg Köhl   +10 more
doaj   +1 more source

Bullous Type 2 Lepra Reaction: A Rare and Significant Case Report

Clinical Case Reports, Volume 13, Issue 1, January 2025.
ABSTRACT Bullous type 2 lepra reactions are a rare initial presentation in leprosy that can complicate the disease with vesiculo‐bullous lesions. Early recognition and differentiation from other bullous disorders are critical for timely corticosteroid and multidrug therapy initiation to improve patient outcomes.
Hrithik Dakssesh Putta Nagarajan, Balakrishnan Kamaraj, Keerthivasan Selvanathan, Pruthvi Raj Kukunoor, Katta Manichandana, Katta Manideep, Biki Kumar Sah   +6 more
wiley   +1 more source